Thomas Tegos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Tegos has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Effrosyni Koutsouraki
1st Department of Neurology, AHEPA University Hospital, 54636 Thessaloniki, Greece
3 shared publications - Magda Tsolaki
1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
3 shared publications - Anastasia Konsta
First Department of Psychiatry, “Papageorgiou” General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Christos Savopoulos
First Propaedeutic Department of Internal Medicine & Acute Stroke Unit, AHEPA University Hospital, 546 36 Thessaloniki, Greece
2 shared publications - Dimitrios Kazis
Third Department of Neurology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - John Papatriantafyllou
1st Department of Neurology, Aiginition University Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
2 shared publications
Latest Publications
- Open Access
- 23 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1311
Intraepidermal Nerve Fiber Density as an Indicator of Neuropathy Predisposition: A Systematic Review with Meta-Analysis
Background/Objectives: Skin spot biopsy is the gold standard for diagnosing small fiber neuropathy. A systematic approach to intraepidermal nerve fiber density (IENFD) was conducted to estimate its value precisely in healthy and neuropathic subjects, independent of the neuropathy disease. The findings will serve as a guidance model for IENFD as an indicator of neuropathy predisposition. It was also investigated how IENFD was influenced by age, gender, and neuropathy. Methods: A systematic search of PubMed, Web of Science, and ScienceDirect was conducted to identify clinical studies from 1997 to 2022 concerning IENFD in healthy and neuropathic adult populations. Data were retrieved from longitudinal cohort studies, including 5–188 healthy and 6–40 neuropathic patients. Multilevel meta-regression was employed to assess associations between the anatomical region, mean patient age, and male/female ratio with IENFD. This method accounted for correlations between multiple outcomes from the same survey, offering a more nuanced analysis than standard meta-regression. Results: In the healthy population, the estimated (95% CI) IENFD values (fibers/mm) were 21.4 (19.9, 22.9) in the thigh, 17.7 (15.3, 20.1) in the forearm, 12.9 (11.8, 14.0) in the distal leg, 11.3 (6.1, 16.5) in the fingers, and 6.5 (4.4, 8.6) in the toes. The corresponding estimates in the neuropathic population were 17.2 (15.2, 19.2) in the thigh, 6.3 (2.3, 10.2) in the forearm, 5.1 (3.8, 6.4) in the distal leg, and 2.0 (0.0, 5.7) in the toes. In a healthy population, IENFD decreased with aging by 1.35 fibers/mm every 5 years (p < 0.001). Gender dimorphism in IENFD existed, with females showing higher values in the distal leg (13.6–10.5) compared to males (9.3–7.2). Conclusions: The systematic study and meta-analysis integrate evidence of IENFD in skin biopsies. This analysis reconciles findings from various methodologies and populations over two decades. Meta-regression techniques address variability due to biopsy site, fixation protocols, immunohistochemical markers, and demographics. To reduce future study heterogeneity, using the thigh is advisable as it shows the least variability. Additionally, standardizing the biopsy site internationally will ensure comparability. These findings urge further investigation into IENFD changes in neurodegenerative diseases and whether IENFD can be a reliable prognostic marker for neuropathy diagnosis.
- 23 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1311
Open AccessIntraepidermal Nerve Fiber Density as an Indicator of Neuropathy Predisposition: A Systematic Review with Meta-Analysis
Background/Objectives: Skin spot biopsy is the gold standard for diagnosing small fiber neuropathy. A systematic approach to intraepidermal nerve fiber density (IENFD) was conducted to estimate its value precisely in healthy and neuropathic subjects, independent of the neuropathy disease. The findings will serve as a guidance model for IENFD as an indicator of neuropathy predisposition. It was also investigated how IENFD was influenced by age, gender, and neuropathy. Methods: A systematic search of PubMed, Web of Science, and ScienceDirect was conducted to identify clinical studies from 1997 to 2022 concerning IENFD in healthy and neuropathic adult populations. Data were retrieved from longitudinal cohort studies, including 5–188 healthy and 6–40 neuropathic patients. Multilevel meta-regression was employed to assess associations between the anatomical region, mean patient age, and male/female ratio with IENFD. This method accounted for correlations between multiple outcomes from the same survey, offering a more nuanced analysis than standard meta-regression. Results: In the healthy population, the estimated (95% CI) IENFD values (fibers/mm) were 21.4 (19.9, 22.9) in the thigh, 17.7 (15.3, 20.1) in the forearm, 12.9 (11.8, 14.0) in the distal leg, 11.3 (6.1, 16.5) in the fingers, and 6.5 (4.4, 8.6) in the toes. The corresponding estimates in the neuropathic population were 17.2 (15.2, 19.2) in the thigh, 6.3 (2.3, 10.2) in the forearm, 5.1 (3.8, 6.4) in the distal leg, and 2.0 (0.0, 5.7) in the toes. In a healthy population, IENFD decreased with aging by 1.35 fibers/mm every 5 years (p < 0.001). Gender dimorphism in IENFD existed, with females showing higher values in the distal leg (13.6–10.5) compared to males (9.3–7.2). Conclusions: The systematic study and meta-analysis integrate evidence of IENFD in skin biopsies. This analysis reconciles findings from various methodologies and populations over two decades. Meta-regression techniques address variability due to biopsy site, fixation protocols, immunohistochemical markers, and demographics. To reduce future study heterogeneity, using the thigh is advisable as it shows the least variability. Additionally, standardizing the biopsy site internationally will ensure comparability. These findings urge further investigation into IENFD changes in neurodegenerative diseases and whether IENFD can be a reliable prognostic marker for neuropathy diagnosis.
- Open Access
- 23 May 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (6) , 98
Online Occupational Therapy as a Rehabilitation Intervention for Parkinson’s Disease: A Systematized Review
Background/Objectives: Occupational therapy (OT) plays a crucial role in addressing functional limitations and promoting independence in Parkinson’s disease (PD) patients. OT interventions target motor skills, daily activities, and engagement in meaningful tasks. Telehealth, the remote delivery of healthcare services, has expanded access to rehabilitation, including OT for PD. While several studies have examined the benefits of online OT, a comprehensive assessment of its impact on functional outcomes and quality of life (QoL) is needed. This review aimed to evaluate the effects of online OT interventions on functional outcomes and QoL of patients with PD. Methods: This review employed a systematized approach, guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, though it did not constitute a full systematic review or meta-analysis. A comprehensive search was conducted across PubMed, Web of Science, Scopus, and Embase databases between August 2023 and September 2024. The search targeted randomized controlled trials (RCTs) investigating telerehabilitation interventions in OT for individuals with PD. Studies were excluded if they were not published in English, did not employ an RCT design, or lacked a focus on telerehabilitation within the scope of occupational therapy for PD. Additionally, systematic reviews, meta-analyses, qualitative studies, and studies without measurable outcomes were excluded. Nine studies met the inclusion criteria, with four involving occupational therapists directly and five evaluating interventions within the scope of OT practice. Results: The primary outcomes of this review focused on mobility improvements in PD patients, assessed through gait metrics such as gait speed, stride length, and gait variability. Secondary outcomes evaluated the impact of telerehabilitation on QoL, using tools such as the Parkinson’s Disease Questionnaire (PDQ-39) and other disease-specific instruments. The findings demonstrated that online OT interventions significantly improved motor skills, cognitive function, and activities of daily living in PD patients. Furthermore, these interventions enhanced overall well-being and QoL. The remote format fostered sustained engagement and adherence to therapy, contributing to better long-term outcomes. Conclusions: Online OT interventions show promising potential for improving functional outcomes and QoL in PD patients. These findings underscore the potential of telehealth to expand access to OT services, thereby enhancing long-term rehabilitation outcomes for this population.
- 23 May 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (6) , 98
Open AccessOnline Occupational Therapy as a Rehabilitation Intervention for Parkinson’s Disease: A Systematized Review
Background/Objectives: Occupational therapy (OT) plays a crucial role in addressing functional limitations and promoting independence in Parkinson’s disease (PD) patients. OT interventions target motor skills, daily activities, and engagement in meaningful tasks. Telehealth, the remote delivery of healthcare services, has expanded access to rehabilitation, including OT for PD. While several studies have examined the benefits of online OT, a comprehensive assessment of its impact on functional outcomes and quality of life (QoL) is needed. This review aimed to evaluate the effects of online OT interventions on functional outcomes and QoL of patients with PD. Methods: This review employed a systematized approach, guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, though it did not constitute a full systematic review or meta-analysis. A comprehensive search was conducted across PubMed, Web of Science, Scopus, and Embase databases between August 2023 and September 2024. The search targeted randomized controlled trials (RCTs) investigating telerehabilitation interventions in OT for individuals with PD. Studies were excluded if they were not published in English, did not employ an RCT design, or lacked a focus on telerehabilitation within the scope of occupational therapy for PD. Additionally, systematic reviews, meta-analyses, qualitative studies, and studies without measurable outcomes were excluded. Nine studies met the inclusion criteria, with four involving occupational therapists directly and five evaluating interventions within the scope of OT practice. Results: The primary outcomes of this review focused on mobility improvements in PD patients, assessed through gait metrics such as gait speed, stride length, and gait variability. Secondary outcomes evaluated the impact of telerehabilitation on QoL, using tools such as the Parkinson’s Disease Questionnaire (PDQ-39) and other disease-specific instruments. The findings demonstrated that online OT interventions significantly improved motor skills, cognitive function, and activities of daily living in PD patients. Furthermore, these interventions enhanced overall well-being and QoL. The remote format fostered sustained engagement and adherence to therapy, contributing to better long-term outcomes. Conclusions: Online OT interventions show promising potential for improving functional outcomes and QoL in PD patients. These findings underscore the potential of telehealth to expand access to OT services, thereby enhancing long-term rehabilitation outcomes for this population.
- Open Access
- 2 May 2025
- Published by MDPI AG in Journal of Dementia and Alzheimer's Disease
- Vol. 2 (2) , 13
Effects of Alzheimer’s Dementia Treatment on Agitation and Aggression: A Systematic Review
Introduction—Aim: Agitation and aggression are common symptoms in people with Alzheimer’s disease and other dementias. This systematic review outlines the current evidence for the effect of antidementia treatments on agitation and aggression in patients with Alzheimer’s disease. Methods: The literature search was performed by manually checking articles published since 2000 in the following databases: PubMed, ResearchGate, and Google Scholar, following the PRISMA guidelines. Results: Nineteen double blinded placebo-controlled trials were included. Treatment with galantamine seems to provide more credible evidence for treating or preventing agitation/aggression. Studies on memantine often presented with an improvement of the neuropsychiatric inventory but not specifically on agitation/aggression. The trials on donepezil and rivastigmine either did not include enough information on agitation/aggression or did not provide compelling results. The incidence of agitation as an adverse event was not higher in antidementia treatments compared to placebo. Conclusions: Agitation and aggression are common symptoms of Alzheimer’s disease and have a significant impact on the patient, caregiver, and the broader healthcare system. The current literature lacks robust evidence on which of the antidementia treatments could be used to manage or prevent agitation and aggression in Alzheimer’s disease. In most included studies, no specific scores that assess those symptoms were used. Future research that specifically focuses on different disease phenotypes and behavioral profiles to enhance and facilitate the management of these symptoms is needed.
- 2 May 2025
- Published by MDPI AG in Journal of Dementia and Alzheimer's Disease
- Vol. 2 (2) , 13
Open AccessEffects of Alzheimer’s Dementia Treatment on Agitation and Aggression: A Systematic Review
Introduction—Aim: Agitation and aggression are common symptoms in people with Alzheimer’s disease and other dementias. This systematic review outlines the current evidence for the effect of antidementia treatments on agitation and aggression in patients with Alzheimer’s disease. Methods: The literature search was performed by manually checking articles published since 2000 in the following databases: PubMed, ResearchGate, and Google Scholar, following the PRISMA guidelines. Results: Nineteen double blinded placebo-controlled trials were included. Treatment with galantamine seems to provide more credible evidence for treating or preventing agitation/aggression. Studies on memantine often presented with an improvement of the neuropsychiatric inventory but not specifically on agitation/aggression. The trials on donepezil and rivastigmine either did not include enough information on agitation/aggression or did not provide compelling results. The incidence of agitation as an adverse event was not higher in antidementia treatments compared to placebo. Conclusions: Agitation and aggression are common symptoms of Alzheimer’s disease and have a significant impact on the patient, caregiver, and the broader healthcare system. The current literature lacks robust evidence on which of the antidementia treatments could be used to manage or prevent agitation and aggression in Alzheimer’s disease. In most included studies, no specific scores that assess those symptoms were used. Future research that specifically focuses on different disease phenotypes and behavioral profiles to enhance and facilitate the management of these symptoms is needed.
- Open Access
Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease
Coronavirus disease 2019 (COVID-19) is frequently accompanied by neurological manifestations such as headache, delirium, and epileptic seizures, whereas ageusia and anosmia may appear before respiratory symptoms. Among the various neurological COVID-19-related comorbidities, Parkinson’s disease (PD) has gained increasing attention. Some cases of PD disease have been linked to COVID-19, and both motor and non-motor symptoms in Parkinson’s disease patients frequently worsen following SARS-CoV-2 infection. Although it is still unclear whether PD increases the susceptibility to SARS-CoV-2 infection or whether COVID-19 increases the risk of or unmasks future cases of PD, emerging evidence sheds more light on the molecular mechanisms underlying the relationship between these two diseases. Among them, angiotensin-converting enzyme 2 (ACE2), a significant component of the renin-angiotensin system (RAS), seems to play a pivotal role. ACE2 is required for the entry of SARS-CoV-2 to the human host cells, and ACE2 dysregulation is implicated in the severity of COVID-19-related acute respiratory distress syndrome (ARDS). ACE2 imbalance is implicated in core shared pathophysiological mechanisms between PD and COVID-19, including aberrant inflammatory responses, oxidative stress, mitochondrial dysfunction, and immune dysregulation. ACE2 may also be implicated in alpha-synuclein-induced dopaminergic degeneration, gut–brain axis dysregulation, blood–brain axis disruption, autonomic dysfunction, depression, anxiety, and hyposmia, which are key features of PD.
Open AccessExploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease
Coronavirus disease 2019 (COVID-19) is frequently accompanied by neurological manifestations such as headache, delirium, and epileptic seizures, whereas ageusia and anosmia may appear before respiratory symptoms. Among the various neurological COVID-19-related comorbidities, Parkinson’s disease (PD) has gained increasing attention. Some cases of PD disease have been linked to COVID-19, and both motor and non-motor symptoms in Parkinson’s disease patients frequently worsen following SARS-CoV-2 infection. Although it is still unclear whether PD increases the susceptibility to SARS-CoV-2 infection or whether COVID-19 increases the risk of or unmasks future cases of PD, emerging evidence sheds more light on the molecular mechanisms underlying the relationship between these two diseases. Among them, angiotensin-converting enzyme 2 (ACE2), a significant component of the renin-angiotensin system (RAS), seems to play a pivotal role. ACE2 is required for the entry of SARS-CoV-2 to the human host cells, and ACE2 dysregulation is implicated in the severity of COVID-19-related acute respiratory distress syndrome (ARDS). ACE2 imbalance is implicated in core shared pathophysiological mechanisms between PD and COVID-19, including aberrant inflammatory responses, oxidative stress, mitochondrial dysfunction, and immune dysregulation. ACE2 may also be implicated in alpha-synuclein-induced dopaminergic degeneration, gut–brain axis dysregulation, blood–brain axis disruption, autonomic dysfunction, depression, anxiety, and hyposmia, which are key features of PD.
- Open Access
- 26 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (6) , 691
Assess of Combinations of Non-Pharmacological Interventions for the Reduction of Irritability in Patients with Dementia and their Caregivers: A Cross-Over RCT
Introduction: Dementia is a very common disorder that affects people over 65 years old all over the world. Apart from the cognitive decline, Behavioral and Psychological Symptoms of Dementia (BPSD) are a crucial matter in dementia, because they affect up to 90% of the patients during the course of their illness. Irritability has been found to be a common BPSD and one of the most distressing behaviors for the caregivers. The aim of the current study was to explore the efficacy of a combination of non-pharmacological interventions to treat irritability. Methods: Sixty patients with different types and stages of dementia with irritability were participated in a cross-over RCT. Three non-pharmacological interventions were used; (a) Validation Therapy (VT)/Psycho-educational program, (b) Aromatherapy/massage and (c) Music Therapy (MT). The study assessed the three non-pharmacological interventions in order to find the most effective combination of the interventions. This study did not compare pharmacological and non-pharmacological treatments. The interventions lasted for five days. There was no drop-out rate. All patients were assessed at baseline using Mini Mental State of Examination (MMSE), Addenbrooke’s Cognitive Examination Revised (ACE-R), Geriatric Depression Scale (GDS), Functional Rating Scale for symptoms in dementia (FRSSD), and Neuropsychiatric Inventory (NPI) (sub questions for irritability). Only NPI used for the assessment after each intervention. The analyses used categorical variables, Wilcoxon signed-rank test, Chi-square test and z value score. Results: The most effective combination of non-pharmacological interventions was Aromatherapy/massage (p = 0.003)-VT plus Psycho-educational program (p = 0.014) plus MT (p = 0.018). The same combination was the most effective for the caregivers’ burden, too (p = 0.026). Conclusions: The above combination of non-pharmacological interventions can reduce irritability in patients with dementia and caregivers’ burden.
- 26 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (6) , 691
Open AccessAssess of Combinations of Non-Pharmacological Interventions for the Reduction of Irritability in Patients with Dementia and their Caregivers: A Cross-Over RCT
Introduction: Dementia is a very common disorder that affects people over 65 years old all over the world. Apart from the cognitive decline, Behavioral and Psychological Symptoms of Dementia (BPSD) are a crucial matter in dementia, because they affect up to 90% of the patients during the course of their illness. Irritability has been found to be a common BPSD and one of the most distressing behaviors for the caregivers. The aim of the current study was to explore the efficacy of a combination of non-pharmacological interventions to treat irritability. Methods: Sixty patients with different types and stages of dementia with irritability were participated in a cross-over RCT. Three non-pharmacological interventions were used; (a) Validation Therapy (VT)/Psycho-educational program, (b) Aromatherapy/massage and (c) Music Therapy (MT). The study assessed the three non-pharmacological interventions in order to find the most effective combination of the interventions. This study did not compare pharmacological and non-pharmacological treatments. The interventions lasted for five days. There was no drop-out rate. All patients were assessed at baseline using Mini Mental State of Examination (MMSE), Addenbrooke’s Cognitive Examination Revised (ACE-R), Geriatric Depression Scale (GDS), Functional Rating Scale for symptoms in dementia (FRSSD), and Neuropsychiatric Inventory (NPI) (sub questions for irritability). Only NPI used for the assessment after each intervention. The analyses used categorical variables, Wilcoxon signed-rank test, Chi-square test and z value score. Results: The most effective combination of non-pharmacological interventions was Aromatherapy/massage (p = 0.003)-VT plus Psycho-educational program (p = 0.014) plus MT (p = 0.018). The same combination was the most effective for the caregivers’ burden, too (p = 0.026). Conclusions: The above combination of non-pharmacological interventions can reduce irritability in patients with dementia and caregivers’ burden.
- Open Access
- 19 January 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (2) , 130
Non-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia
Background: Aberrant motor behaviour or wandering refers to aimless movement without a specific purpose. Wandering is common in patients with dementia and leads to early institutionalization and caregivers’ burden. Non-pharmacological interventions should be also considered as a first-line solution for the wandering because current pharmacological treatment has serious side-effects. Methods: A cross-over randomised controlled trial (RCT) with 60 participants of all stages and different types of dementia was conducted in Greece. The sample was randomly assigned in 6 different groups of 10 participants each. Every intervention lasted for 5 days, and there were 2 days as a wash-out period. There was no drop-out rate. The measurements used were the Mini Mental State Examination (MMSE), Addenbrooke’s Cognitive Examination Revised (ACE-R), Geriatric Depression Scale (GDS), Functional Rating Scale for Symptoms in Dementia (FRSSD), and Neuropsychiatric Inventory (NPI). The interventions that were evaluated were reminiscence therapy (RT), music therapy (MT), and physical exercise (PE). Results: NPI scores were reduced in the group receiving PE (p = 0.006). When MT (p = 0.018) follows PE, wandering symptoms are reduced further. RT should follow MT in order to reduce wandering more (p = 0.034). The same combination was effective for the caregivers’ burden as well; PE (p = 0.004), MT (p = 0.036), RT (p = 0.039). Conclusions: An effective combination that can reduce wandering symptoms in all stages and types of dementia was found: The best order was PH-MT-RT. The same combination in the same order reduced caregivers’ burden.
- 19 January 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (2) , 130
Open AccessNon-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia
Background: Aberrant motor behaviour or wandering refers to aimless movement without a specific purpose. Wandering is common in patients with dementia and leads to early institutionalization and caregivers’ burden. Non-pharmacological interventions should be also considered as a first-line solution for the wandering because current pharmacological treatment has serious side-effects. Methods: A cross-over randomised controlled trial (RCT) with 60 participants of all stages and different types of dementia was conducted in Greece. The sample was randomly assigned in 6 different groups of 10 participants each. Every intervention lasted for 5 days, and there were 2 days as a wash-out period. There was no drop-out rate. The measurements used were the Mini Mental State Examination (MMSE), Addenbrooke’s Cognitive Examination Revised (ACE-R), Geriatric Depression Scale (GDS), Functional Rating Scale for Symptoms in Dementia (FRSSD), and Neuropsychiatric Inventory (NPI). The interventions that were evaluated were reminiscence therapy (RT), music therapy (MT), and physical exercise (PE). Results: NPI scores were reduced in the group receiving PE (p = 0.006). When MT (p = 0.018) follows PE, wandering symptoms are reduced further. RT should follow MT in order to reduce wandering more (p = 0.034). The same combination was effective for the caregivers’ burden as well; PE (p = 0.004), MT (p = 0.036), RT (p = 0.039). Conclusions: An effective combination that can reduce wandering symptoms in all stages and types of dementia was found: The best order was PH-MT-RT. The same combination in the same order reduced caregivers’ burden.
- Open Access
- 27 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (11) , 2357
Evaluation of Effects of Diabetes Mellitus, Hypercholesterolemia and Hypertension on Bell’s Palsy
The aim of this study is to evaluate the effects of diabetes mellitus, hypertension and hypercholesterolemia on the clinical presentation and outcome of Bell’s palsy. The study (comorbidity) group consisted of 50 patients with Bell’s palsy associated with diabetes, hypertension, or hypercholesterolemia; the control group included 46 patients with Bell’s palsy, but without comorbid diseases. The House–Brackmann grading system (I to VI) was used in order to assess the initial and final facial functions. Both groups of patients were treated with steroids and the antiviral agent acyclovir. The mean severity of initial facial paralysis was more significant in diabetes, hypercholesterolemia, and hypertension, in comparison to the control group. Patients suffering from Bell’s palsy and concomitant comorbidities have a poorer prognosis (HB III-VI) compared to patients without comorbidities. Increased glycosylated hemoglobin A1c levels (>6.7%) were significantly correlated with unsatisfactory facial recovery. The pathogenetic mechanisms by which diabetes, hypercholesterolemia, and hypertension affect the vasa nervosum of facial nerve have been described.
- 27 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (11) , 2357
Open AccessEvaluation of Effects of Diabetes Mellitus, Hypercholesterolemia and Hypertension on Bell’s Palsy
The aim of this study is to evaluate the effects of diabetes mellitus, hypertension and hypercholesterolemia on the clinical presentation and outcome of Bell’s palsy. The study (comorbidity) group consisted of 50 patients with Bell’s palsy associated with diabetes, hypertension, or hypercholesterolemia; the control group included 46 patients with Bell’s palsy, but without comorbid diseases. The House–Brackmann grading system (I to VI) was used in order to assess the initial and final facial functions. Both groups of patients were treated with steroids and the antiviral agent acyclovir. The mean severity of initial facial paralysis was more significant in diabetes, hypercholesterolemia, and hypertension, in comparison to the control group. Patients suffering from Bell’s palsy and concomitant comorbidities have a poorer prognosis (HB III-VI) compared to patients without comorbidities. Increased glycosylated hemoglobin A1c levels (>6.7%) were significantly correlated with unsatisfactory facial recovery. The pathogenetic mechanisms by which diabetes, hypercholesterolemia, and hypertension affect the vasa nervosum of facial nerve have been described.